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Mohammad H. Eslami, MD,a James T. McPhee, MD,b Jessica P. Simons, MD,a Andres Schanzer, MD,a
and Louis M. Messina, MD,a Worcester, Mass
Objective: This study compared, at a national level, trends in utilization, mortality, and stroke after carotid angioplasty
and stenting (CAS) and carotid endarterectomy (CEA) from 2005 to 2007.
Methods: The Nationwide Inpatient Sample (NIS) was queried for patient discharges with International Classification of
Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes for CAS and CEA. The primary outcomes were
in-hospital mortality, stroke, hospital charges, and discharge disposition. Subgroup analyses were performed to evaluate
these outcomes by neurologic presentation using 2 and multivariable logistic regression.
Results: Of the 404,256 discharges for carotid revascularization, CAS utilization was 66% higher in 2006 than in 2005
(9.3% vs 14%, P .0004). Crudemortality, stroke, andmedian charges remained higher for CAS than for CEA; discharge
to home was more common after CEA. Results improved from 2005 to 2007. By logistic regression of the total cohort
from 2005 to 2006, CASwas independently predictive of mortality (odds ratio [OR], 1.47; 95% confidence interval [CI],
1.08-2.00; P < .0001). Independent predictors of stroke included CAS (OR, 1.43; 95% CI, 1.18-1.73; P < .0001) and
symptomatic disease (OR, 2.4; 95% CI, 2.06-2.93;P < .0001). Among subgroups based on neurological presentation,
regression showed that CAS significantly increased the odds of stroke in asymptomatic patients (OR, 1.6; 95% CI,
1.2-2.0; P  .0003). Among symptomatic patients, CAS increased the odds of in-hospital death (OR, 3.0; 95% CI,
1.7-5.1, P < .0001) and trended toward significance for stroke (OR, 1.7; 95% CI, 1.0-2.8; P  .0569).
Conclusion: Utilization of CAS has increased from the years 2005 to 2007 with some improvements in the outcome.
Despite improvements in outcome, resource utilization remains significantly higher for CAS than CEA. (J Vasc Surg
2011;53:307-15.)
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tSince the endovascular technique was first described in
the early 1990s,1,2 proponents of carotid artery stenting
(CAS) have cited its less invasive nature as an alternative to
carotid endarterectomy particularly in “high-risk” patients3
without a clear definition of such patients. Several studies
have compared the postprocedure results of CAS and ca-
rotid endarterectomy (CEA) in both symptomatic and
asymptomatic patients.3-7 Results are conflicting and de-
bate persists about the role of CAS in the treatment of
carotid artery stenosis. Previous work by our group com-
paring CAS with CEA shortly after CAS approval by the
Food and Drug Administration (FDA) in March of 2004,
demonstrated higher morbidity and mortality associated
with CAS.8,9 However, discrepancies in the risk-adjusted
clinical outcomes have not tempered enthusiasm for this
procedure which is performed often outside of Center for
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y different specialties.10
In addition to the risk-adjusted clinical outcome dis-
repancies between the two procedures, cost and resource
tilization must be compared. Two procedures are consid-
red to achieve clinical equipoise once outcomes, resource
tilizations, and procedural costs are similar. Previous stud-
es have demonstrated that CAS may be associated with
ncreased charges when compared directly to CEA.11-13
sing a Markov type decision model, studies14,15 have
uggested CAS to be more costly given the current clinical
utcomes. At the national level, we have shown that CAS
as associated with higher cost utilization in 2005, the first
ear after this procedure was approved.9 However, as pro-
iders gain familiarity with new techniques, results often
mprove and this may lead to the CAS becoming more
cost-effective.”
The purpose of this study was to perform a national,
opulation-based, observational study to evaluate the out-
omes and resource utilization for CAS and CEA during
he years 2005 to 2007 using the specific International
lassification of Diseases Ninth Revision, Clinical Modifica-
ion (ICD-9-CM) code for CAS that became available in
004 after FDA approval. We sought to compare trends in
utcomes and resource utilization during these first 3 years,
he most recent available data, examining whether utiliza-
ion of CAS has increased since US FDA approval. We also
valuated whether such an increase in utilization had led to
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February 2011308 Eslami et alimproved outcomes or decreased resource utilization. The
postprocedure outcomes (death and stroke) and resource
utilization may ultimately determine the best treatment for
patients with carotid artery stenosis.
METHODS
The Nationwide Inpatient Sample (NIS) was queried
for calendar years 2005 to 2007, the most recent available
data, for patient discharges after carotid revascularization.
This represents a stratified sample of 20% of nonfederal US
community hospitals from participating states, containing
information for approximately 7 million hospital dis-
charges, including academic and specialty hospitals
(http://www.hcup-us.ahrq.gov/nisoverview.jsp).16 The
methodology is similar to that used in our previously pub-
lished studies.8,9 Briefly, the database was first queried to
identify all patients undergoing carotid revascularization for
carotid artery stenosis using ICD-9-CM codes for either CAS
(ICD-9-CM procedure code 00.63) or CEA (38.12)17 and
further subdivided based on the absence (433.10) or presence
of neurological symptoms (433.11).18 If a patients’ dis-
charge diagnosis (diagnostic fields 1-15) was “carotid ar-
tery without mention of stroke” with no accompanying
secondary diagnosis for transient ischemic attack (TIA),
they were classified as “asymptomatic.” Patients were con-
sidered symptomatic if they had either a secondary diagno-
sis of stroke or TIA. Patients who had a combined CAS and
CEA codes, less than 1% of patients, were excluded from
this study to allow for homogeneity of the cohorts and
better comparison between the two groups.
Demographic information including age at admission,
gender, and race was collected. Race information was ex-
cluded from all explanatory analyses because of the high
rate (20%) of missing values. Records for patients’ age
18 or 100 years old were also excluded. Comorbid
conditions were identified using the Elixhauser method.19
The identified cohort of patient discharges was ana-
lyzed for codes for in-hospital death and postprocedure
stroke, the primary outcome measures of this analysis.
In-hospital death is available directly in the NIS dataset; it is
assigned as death due to any cause at any point in time
during the index hospitalization. Postprocedure stroke was
identified among secondary discharge diagnoses using a
specific ICD-9-CM code (997.02) for this complication.18
The secondary outcome measures for this study included
resource utilization, namely length of stay (LOS) during
the index hospital admission stay, total hospital charges,
and discharge disposition similar to our prior publication.9
Detailed specific procedure cost information is lacking in
the NIS, therefore, the total hospital charges were used as a
surrogate for cost information. Discharges of the surviving
patients during the index admissions were dichotomized
into either discharge to home (with or without services), or
“other” that included discharges to another facility, includ-
ing a skilled nursing facility or nursing home.
To comment on trends in both utilization of CAS for
carotid artery revascularization and in outcomes after CAS,
we compared the primary and secondary outcomes be- gween CAS and CEA during the first complete 3 calendar
ears (2005-2007), which is the most currently available
ata.
Statistical analysis. Univariate analyses according to
rocedure type and year were conducted using Rao-Scott
or categorical data and survey-weighted analysis of vari-
nce for continuous data for all specified end points, with
 .05 considered statistically significant. As previously
escribed, the Elixhauser comorbidity software was used to
dentify patient comorbidities for univariate and multivari-
te analyses.19 This is a very powerful software tool that
llows for accurate identification of pre-existing medical
omorbidities. Admittedly, comprehensible risk stratifica-
ion is not possible, as we have previously noted.8,9 Sub-
roup analyses according to neurologic presentation were
arried out in an analogous fashion.
Multivariate logistic regression was performed to deter-
ine which factors were independently predictive of post-
perative stroke and death. Covariates controlled for in this
odel included gender, age, comorbid conditions, presen-
ation type, procedure type, and year of the procedure,
ospital teaching status, and hospital bed size. Predictors of
n-hospital death were evaluated in an analogous fashion,
ut with presence of a postprocedure stroke used as an
dditional covariate in these models. Statistical analyses
ere performed with advanced survey procedures when-
ver possible, using SAS (v9.1, Cary, NC). Data are pre-
ented in their weighted frequencies, as previously de-
cribed, and the missing data were excluded by SAS from
he analysis.20
ESULTS
Patient discharge characteristics. From the years
005 to 2007, an estimated 404,256 patient discharges
fter carotid revascularization occurred in the United
tates. Each year contributed equally to the patient sample.
he majority of carotid revascularization was performed by
EA (88.6% vs CAS, 11.4%). Overall, 54% of these revas-
ularizations were performed at non-teaching institutions
P  .05). A proportionately higher percentage of CAS
rocedures were performed at the teaching hospitals com-
ared to the non-teaching institutions (60.7% vs 39.3%;
 .001). Large hospitals, as defined by the American
ospital Association’s annual survey of hospitals, per-
ormed the majority of carotid revascularizations but no
tatistically significant difference across the procedure type
as noted among the large hospitals; 73.3% of CAS proce-
ures and 67.7% of CEA procedures (P  .18) were per-
ormed at these hospitals. There was an initial significant
ncrease for CAS utilization for carotid revascularization
omparing 2005 to 2006 (9.3% vs 14% absolute values of
he total procedures; P  .004) but no such increase was
oted from 2006 to 2007 (Fig 1). Detailed characteristics
f the cohort can be found in Table I. Asymptomatic
isease was far more common, comprising 91.8% of the
ohort. Median age and age distribution was similar be-
ween the two procedures with an equal number of octo-
enarians represented in both groups. Overall, 57.8%
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Volume 53, Number 2 Eslami et al 309of revascularizations were performed on male patients.
Among the patients with CAS, this discrepancy was even
more pronounced with female patients constituting only
38.6% of patients with CAS (CEA, 57.4% men, 42.6%
women, P  .001). Gender differences between the symp-
tomatic patients did not achieve statistical significance (Ta-
Fig 1. Carotid revascularization 2005 to 2007. a, Over
of the type of revascularizations at teaching and lar
endarterectomy.
Table I. Carotid revascularization patient characteristics,
2005-2007
Factor Weighted N (%)
Year
2005 133,461 (33.0)
2006 137,344 (34.0)
2007 133,451 (33.0)
Age group (in years)
60 50,095 (12.4)
60-69 116,434 (28.8)
70 237,728 (58.8)
Gender
Male 233,425 (57.8)
Female 170,599 (42.2)
Race (missing in 10% of records)
White 265,783 (89.4)
Non-white 31,629 (10.6)
Presentation type
Asymptomatic 372,069 (92.0)
Symptomatic 32,188 (8.0)
Transient ischemic attack 16,600 (4.1)
Stroke 16,005 (4.0)
Procedure type
CEA 358,058 (88.6)
CAS 46,198 (11.4)
Hospital type
Non-teaching 220,763 (54.6)
Teaching 183,407 (45.4)
Hospital bed size
Small 36,977 (9.1)
Medium 90,838 (22.5)
Large 276,356 (68.4)
CAS, Carotid angioplasty and stenting; CEA, carotid endarterectomy.ble II). Of the studied comorbidities that displayed a sig- uificantly different distribution between procedure types,
nly congestive heart failure (CHF; 11.5% vs 6.9%; P 
0001) and renal failure (4.0% vs 2.6%, P  .0001) were
ore commonly associated with CAS; hypertension (65.3%
s 71.1%; P  .0001), chronic lung disease (19.7% vs
2.0%; P .0009), and obesity (4.0% vs 5.4%; P .0001)
ere more commonly associated with CEA (Table II).
Crude analysis of mortality and postprocedure
troke. Table III summarizes the univariate analyses of
ostoperative outcomes and resource utilization for both
rocedures. On univariate analysis of the overall cohort
Table IIIa), patients with CAS were more than twice as
ikely to die in the hospital as patients with CEA (0.84% vs
.42%; P  .0024). CAS was also significantly associated
ith a higher rate of postprocedure stroke (1.4% vs 0.96%;
 .0001). Univariate analysis of the asymptomatic sub-
roup (Table IIIb) revealed similar trends, with higher
ortality rates in the CAS group; however, this did not
each statistical significance (0.39% vs 0.56%; P  .0824).
troke rate was significantly higher among asymptomatic
atients with CAS (1.3% vs 0.86%; P  .008). The symp-
omatic cohort (Table IIIc) also had a significantly higher
eath rate (3.9% vs 1.2%; P  .0002) than that associated
ith CAS. The stroke rates were also higher among the
AS group but did not achieve statistical significance (3.1%
s 2.1%; P  .123).
Trends for crude postoperative mortality and
troke from 2005 to 2007. Figures 2 and 3, respectively,
ummarize the postoperative mortality and stroke data for
he overall patient population and for different patient
ohorts. Overall (Figs 2, a and 3, a), the postprocedure
troke and mortality rates were statistically significantly
igher among the CAS group compared with the CEA
roup from 2005 to 2007. This was true in years 2005 and
006. In the year 2007, no statistically significant differ-
nce was observed between the two groups mainly to an
mprovement in the CAS results, as the CEA results were
otid revascularization in the US. b, Overall distribution
spitals. CAS, Carotid artery stenting; CEA, carotidall car
ge honiformly excellent. A similar trend was noted for asymp-
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February 2011310 Eslami et altomatic patients (Figs 2, b and 3, b). Among the symptom-
atic patients (Fig 2, c), crude mortality was statistically
higher for the patients with CAS but an improving trend
was observed such that the mortality rates for CAS de-
creased from 4.6% in 2005 to 3.6% in 2007, although the
difference was not statistically significant. A similar drop in
postprocedure stroke (Fig 3, c) was also noted (4.1% in
2005 vs 2.1% in 2007).
Crude analysis of resource utilization. On univari-
ate analysis of the overall cohort, median LOS was the same
(1 day) among patients with CAS and patients with CEA
(Table IIIa); comparisons of the means were significantly
different, however, with CAS having a higher mean LOS
(P  .0001). Median hospital charges for CAS were also
significantly higher (P  .0001). Discharge to home was
statistically significantly higher among patients with CEA
(94.4% vs 92.2%; P  .002). Conversely, a statistically
higher portion of patients was discharged to skilled nursing
facilities after CAS. Given that median hospital charges vary
from year to year due to inflation, we compared charges on
a yearly basis between the two procedures. Median charges
for both procedures increased yearly from 2005 to 2007;
the median charges for CAS were statistically higher than
CEA (Table IIa).
Among the subgroup of asymptomatic patients (Table
IIb), median LOS was the same (1 day) among patients
with CAS and CEA; however, comparisons of the means
were similarly significantly less for patients with CEA (P 
.0001). Median hospital charges for CAS were also signif-
icantly higher (P  .0001). Discharge disposition was not
Table II. Univariate analysis of patient characteristics base
disease, 2005 to 2007
Factor
Overall N  404,256
CAS CEA P value
Age group .3482
% 60 12.7 12.4
% 60-69 28.1 28.9
% 70 59.2 58.8
Gender .0001
% Male 61.4 57.4
Comorbidity
% Hypertension 65.3 71.1 .0001
% Diabetes 26.6 27.1 .3622
% Chronic lung disease 19.7 22.0 .0009
% CAD/MI 11.5 11.1 .5273
% CHF 11.5 6.9 .0001
% Valvular disease 7.7 7.1 .1070
% Renal failure 4.0 2.6 .0001
% Obesity 4.0 5.4 .0001
Hospital type .0001
% Teaching 60.7 43.4
Hospital bed size .1828
Small 8.4 9.2
Medium 18.2 23.0
Large 73.3 67.7
CAD/MI, Coronary artery disease/myocardial infarction; CAS, carotid angsignificantly different between the two groups (P .0707). tAmong symptomatic patients (Table IIIc), median
OS was statistically higher for the CAS group (5 vs 4 days;
 .001). Median hospital charges for CAS were also
ignificantly higher (P  .0001). Patients with CEA were
ignificantly more likely to be discharged home than pa-
ients with CAS (84.8% vs 73.5%; P  .0001).
Trends for resource utilization for the years 2005
o 2007. Figure 4 depicts the resource utilization. This
hows that every year the total hospital charges, as a surro-
ate of cost, were significantly higher for the CAS proce-
ures. Similarly, overall patient discharges to skilled nursing
acilities were higher for patients with CAS. There was an
mproving trend for discharges to home overall (Fig 4, a)
nd for asymptomatic patients (Fig 4, b) such that in 2007,
lthough a higher percentage of patients with CAS were
ischarged to skilled nursing facilities compared to CEA,
he results are not statistically significant. Such a trend was
ot observed among the symptomatic patients (Fig 4, c).
Multivariable analysis of postprocedure stroke. By
ultivariate logistic regression that adjusts for confounding
ariables, CAS was independently predictive of postproce-
ure stroke (adjusted odds ratio [OR], 1.47; 95% confi-
ence interval [CI], 1.08-2.00; P  .015). Other factors
hat independently predicted postprocedure stroke were
emale gender (1.23, 95% CI, 1.07-1.42) and symptomatic
resentation (2.45, 95% CI, 2.06-2.93; Table IV). Hyper-
ension was actually protective against stroke (OR, 0.74;
5% CI, 0.61-0.89; P .0012). The year of the procedure
2007 vs 2005) did not independently predict postopera-
procedure type for asymptomatic and symptomatic
symptomatic N  372,069 Symptomatic N  32,188
S CEA P value CAS CEA P value
.5567 .1644
.0 11.9 20.1 17.2
.3 29.0 26.0 27.9
.7 59.1 53.9 54.9
.0001 .2321
.7 57.2 62.1 59.7
.7 71.4 .0001 60.4 68.3 .0001
.8 27.3 .3756 24.4 24.7 .8794
.3 21.8 .0020 20.4 22.8 .1418
.8 11.3 .4061 8.1 9.2 .3312
.3 6.9 .0001 13.9 7.7 .0001
.9 7.0 .0264 6.1 8.4 .0177
.9 2.7 .0001 4.2 3.6 .3695
.0 5.3 .0001 4.7 5.7 .2337
.0001 .0001
.0 43.3 69.2 44.4
.2670 .0002
.7 9.3 4.9 8.9
.6 23.0 14.9 23.4
.7 67.7 80.3 67.7
y and stenting; CEA, carotid endarterectomy; CHF, coronary heart failure.d on
A
CA
12
28
59
60
65
26
19
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11
7
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4
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CAS trended toward increased in-hospital mortality (OR,
1.43; 95% CI, 1.18-1.73). After adjusting for other factors,
postprocedure stroke was the strongest predictor of in-
hospital mortality (OR, 26.46; 95% CI, 18.98-36.88; P 
.0001). Symptomatic presentation was associated with a
nearly threefold increase in odds of mortality (OR, 2.99;
95% CI, 2.20-4.07; P  .0001). Advanced age (70),
congestive heart failure, renal failure, and chronic lung
disease also increased in-hospital mortality odds. Year was
Table III. Univariate analysis of postoperative outcomes a
2005 to 2007
(a)
Factor CEA
In-hospital mortality % 0.45
Postoperative stroke % 0.96
Length of stay, in days
Median (range) 1 (0-8.9)
Total hospital charges $
Median (range)
2005: Median (range) 17,511 (29-632,3
2006: Median (range) 18,873 (120-736,
2007: Median (range) 21,169 (100-1,19
Discharge disposition
% Home 94.4
% Rehab, SNF, home services 5.6
(b)
Factor CEA
In-hospital mortality % 0.39
Postoperative stroke % 0.86
Length of stay, in days
Median (range) 1 (0-110)
Total hospital charges $
Median (range)
2005: Median (range) 16,956 (29-632,3
2006: Median (range) 18,223 (145-736
2007: Median (range) 20,603 (100-880
Discharge disposition
% Home 95.3
% Rehab, SNF, home services 4.7
(c)
Factor CEA
In-hospital mortality % 1.2
Postoperative stroke % 2.1
Length of stay, in days
Median (range) 4 (0-110)
Total hospital charges $
Median (range)
2005: Median (range) 29,894 (482-568,1
2006: Median (range) 32,709 (120-506,9
2007: Median (range) 35,112 (303-1,199
Discharge disposition
% Home 84.2
% Rehab, SNF, home services 15.8
CAS, Carotid angioplasty and stenting; CEA, carotid endarterectomy; Reha
(a) Overall cohort; (b) asymptomatic; and (c) symptomatic.not associated with in-hospital mortality (Table IV). aISCUSSION
In this retrospective observational study of the most
ecently available national data (2007), we have found that
uring the first 3 years after FDA approval of CAS, patients
ndergoing CAS had significantly higher overall rates of
ostoperative stroke and in-hospital mortality than those
ndergoing CEA. By separate analysis, for patients with
symptomatic carotid artery stenosis, CAS was associated
ith a higher postoperative stroke rate than CEA. For
ymptomatic patients with carotid artery stenosis, CAS was
esource utilization by presentation type CEA and CAS,
Overall
CAS P value
0.84 .0024
1.4 .0003
.0001
1 (0-10.1)
29,841 (649-508,734) .0001
32,340 (145-806,425) .0001
) 33,485 (157-818,488) .0001
.0211
92.2
7.8
Asymptomatic
CAS P value
0.56 .1195
1.3 .0008
.0001
1 (0-56)
28,853 (649-508,734) .0001
31,366 (145-511,517) .0001
32,446 (157-587,757) .0001
.1048
94.6
5.4
Symptomatic
CAS P value
3.9 .0002
3.1 .1237
.0001
5 (0-169)
49,630 (4176-473,639) .0001
50,946 (4111-806,425) .0001
) 55,605 (5479-818,488) .0001
.0001
74.2
25.8
abilitation; SNF, skilled nursing facility.nd r
41)
605)
9,766
41)
,605)
,011)
51)
71)
,766ssociated with a more than threefold higher mortality rate
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February 2011312 Eslami et althan CEA. Bymultivariate analysis, CAS had higher odds of
postoperative stroke (1.43) and in-hospital mortality
(1.47) than those that underwent CEA. Year of the proce-
dure did not independently affect either in-hospital mortal-
ity or postprocedure stroke. Analyzing the results on a
yearly basis, we observed that the results have improved for
both mortality and morbidity after CAS such that in 2007,
except for mortality rates among symptomatic patients, the
results were comparable. In terms of resource utilization,
overall median total hospital charges were significantly
higher each year for CAS independent of the year of the
procedure. Patients with CAS were more likely to be dis-
charged to a facility other than home (7.1% vs 5.6%; P 
.0016). Yearly analysis showed that the discharges to the
facilities became comparable by 2007 for asymptomatic
patients but remained significantly higher for symptomatic
patients undergoing CAS every year.
As many providers anticipate the definitive results of
randomized controlled trials such as the Carotid Revascu-
larization Endarterectomy vs Stenting Trial (CREST),21
conflicting results have been published regarding the out-
comes of CEA compared to CAS.3,6,8,9,22-24 Despite the
lack of clear evidence, CAS is performed by different spe-
cialties10 and outside of clinical trials8,9 and more com-
monly on asymptomatic patients.8-10 Goodney et al25
recently published the trends for regional carotid revascu-
larization and they noted an increase in the rate of CAS
utilization amongMedicare patients. Our analysis showed a
Fig 2. Outcome: mortality. (a) Overall, (b) asymptomatic, and
(c) symptomatic. CAS, Carotid artery stenting; CEA, carotid
endarterectomy.similar increase in the utilization of CAS from 2005 to t007 and, although the overall total number of revascular-
zation procedures was similar, there was a decrease in the
tilization of CEA for carotid artery revascularizations. As
ost of the patients undergoing revascularization are
symptomatic, the majority of these CAS procedures are
eing performed on asymptomatic patients and, therefore,
utside of CMS guidelines. It is difficult to pinpoint the
eason for this increase in utilization of CAS. It is possible
hat the publication of initial industry-sponsored trials, in
hich non-inferiority of CAS was discussed, such as Yadav
t al’s3 publication, has led to increased enthusiasm for this
rocedure among the specialties that perform only CAS for
arotid revascularizations. In Goodney et al’s25 publica-
ion, one of the highest rates of increase in CAS was in
lorida where vascular surgeons perform only 19% of CAS
rocedures and other providers, who can only perform
AS, perform 81% of these procedures.10
The article by van der Vaart et al26 provides a concise
ummary of many trials reviewing the clinical outcomes.
hey report combined myocardial infarction, stroke, and
ortality rates ranging from 2.1% to 8.3%with stroke ranging
rom 2.1% to 6.9%. In the recent publication of the CREST
rial,27 the overall stroke rate for CAS was twice that of CEA,
lthough the composite adverse events were similar. The
linical observations in the currentwork thatCAS is associated
ith higher in-hospital stroke and mortality rates are similar
ig 3. Outcome: stroke. (a) Overall, (b) asymptomatic, and (c)
ymptomatic. CAS, Carotid artery stenting; CEA, carotid endar-
erectomy.o those of previous population-based studies8,9,28 and
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Volume 53, Number 2 Eslami et al 313large randomized multi-institutional trials.22,24 This study,
similar to our prior publication,9 uses the dedicated ICD-
9-CM codes. In that regard, this study serves not only to
further update the findings of the previous studies but also
validates the previously used ICD-9-CM–based coding
methodology. While recognizing the limitations of the
NIS, our results here and previously8-10 consistently dem-
onstrate that a large number of both CAS and CEA are
performed on asymptomatic patients. The higher overall
postprocedure stroke rate is quite alarming. Although pro-
ponents of CAS may suggest that the CAS patients may be
sicker and, therefore, explain the higher mortality and
stroke rates, in our analysis this did not prove to be the case
as the two groups are relatively similar with regard to
clinical variables. Additionally, using multivariate logistic
regression, which adjusted for all the confounding vari-
ables, similar to our prior publications8,9 and those of a
randomized trail,6 we found that CAS was independently
associated with higher odds of mortality and postprocedure
stroke. The CREST investigators, noting that the compos-
ite adverse events are similar, note that the higher stroke
rates among the CAS patients adversely affects the quality
Fig 4. Median hospital charges and percent discharges
(b) asymptomatic patients, and (c) symptomatic patientsof life among patients who suffer periprocedural stroke.27 cIn our 2008 publication,9 we observed that the gap
etween the outcomes after procedures is “possibly nar-
owing over time.” This analysis indicates that the gap is
losing further except for persistent higher mortality rates
mong the symptomatic patients by 2007. Using the NIS
atabase, in which important clinical data about the pa-
ients are lacking, it is impossible to clearly pinpoint the
actors that have led to improvements of the results in
007. This improvement in CAS outcomes may stem from
umerous factors, but most likely it is the result of the
ncreased experience of the providers in patient selection29
r universal use of some sort of distal protective device
uring the procedure or a “learning curve.”30
In addition to the immediate postprocedure outcomes,
linical equipoise is achieved once the two procedures have
imilar long-term outcomes and similar economic impacts.
sing these metrics, our analysis suggests that CAS leads to
significantly higher economic impact compared with
EA. Total hospital charges as a surrogate of costs have
een previously used to compare outcomes after complex
urgical procedures.11,12 Overall, every year CAS was asso-
iated with significantly greater median total hospital
lled nursing facilities (SNF). (a) Overall patient cohort,
, Carotid artery stenting; CEA, carotid endarterectomy.to skiharges. The median hospital charges for CAS were even
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February 2011314 Eslami et alhigher for symptomatic patients ($19,000 vs $12,000
for the overall cohort). As the overall median LOS for these
patients is similar with the exception for the symptomatic
patients, other factors may lead to this large discrepancy in
charges. Previous economic comparisons have been made
between CEA and CAS, the majority of which have dem-
onstrated significantly increased material costs associated
with CAS compared to CEA.11-15 Although causality can-
not be proven in administrative datasets, we offer that one
possible explanation for the large discrepancy in hospital
charges between CAS and CEA may be related to the
increased postoperative stroke rate which then leads to the
utilization of ancillary services to support these patients.
This is supported by the observation that a greater percent-
age of those patients that underwent CAS required dis-
charge to a facility other than home compared to patients
with CEA. Although it is not possible to directly compare
cost results from single institutional and decision analysis
models to the total hospital charges reported in a large
national database, the trends observed in these studies with
three distinct methodologies are very similar.We appreciate
that it is not possible to draw any firm conclusions about
“cost-effectiveness” of a procedure using retrospective
data, but we agree with Janssen et al15 who conclude that
for CAS to become “cost effective there should be a clear
clinical benefit over CEA.”
The limitations of studies based on administrative data-
sets such as the NIS have been described previously.31 We
have also previously succinctly listed the limitations of such
studies8,9 that have to do with the use of this large adminis-
Table IV. Multivariable analyses of in-hospital mortality a
2007
Factor
In-hospital m
Adjusted OR (95% CI)
Sex, female 0.864 (0.700-1.07)
Age group, ref  60
60-69 1.05 (0.705-1.56)
70 1.52 (1.08-2.13)
Comorbidity
Hypertension 0.396 (0.323-0.486)
Diabetes 1.09 (0.878-1.36)
Chronic lung disease 1.46 (1.17-1.82)
CAD/MI 0.599 (0.41-0.881)
CHF 3.30 (2.52-4.31)
Valvular heart disease 0.858 (0.601-1.23)
Obesity 0.551 (0.298-1.02)
Renal failure 1.66 (1.12-2.44)
Presentation type, symptomatic 3.03 (2.35-3.89)
Procedure type, CAS 1.47 (1.08-2.00)
Year, 2007 vs 2005 0.968 (0.741-1.27)
Non-teaching hospital 0.895 (0.720-1.11)
Hospital bed size, ref  small
Medium 1.21 (0.784-1.86)
Large 1.42 (0.962-2.08)
Postoperative stroke 28.2 (21.7-36.8)
CAD/MI, Coronary artery disease/myocardial infarction; CAS, carotid angi
not applicable; OR, odds ratio; ref, referent.trative database in which important clinical information (type cf lesion, anatomical risk factors, and the use of distal embolic
rotection devices) is missing, long-term follow-up is not
ossible, and coding errors may occur. To minimize these
naccuracies, we used a specific ICD-9-CM code and used
n established comorbidity software to attempt to appro-
riately characterize patients with pre-existing comorbid
onditions.19 Although this comorbidity software has been
alidated,19 it remains imprecise for stratifying the so-called
igh-risk or low-risk patient in a manner comparable to
linical trials and prospective registries.
CAS has gained wide popularity and annual volume
eems to be increasing nationwide, and at the expense of
EA.25 Although the current results are encouraging, CAS
emains prohibitively more expensive. Ultimately, long-
erm follow-up in a randomized unbiased clinical trial will
efine the role of CAS and answer questions about the
cost-effectiveness” of CAS.
ONCLUSION
Despite the ongoing debate in the literature regarding
he use, risks, and benefits of CAS vs CEA, providers have
emonstrated an inability to wait for a clear answer, increas-
ngly performing CAS compared with CEA. Similar to the
esults previously reported by our group, CAS indepen-
ently increased the odds of mortality and stroke compared
ith CEA. Furthermore, the economic impact associated
ith CAS, in terms of hospital charges and discharges to
killed nursing and rehabilitation facilities far outpace that
f CEA despite improving outcome. At the current time,
vailable data indicate that CAS andCEA have not achieved
ostprocedure stroke for carotid revascularization, 2005 to
ty Postprocedure stroke
P value Adjusted OR (95% CI) P value
.1726 1.23 (1.07-1.42) .0044
.0024 .9679
1.02 (0.82-1.27)
0.998 (0.811-1.23)
.0001 0.773 (0.660-0.905) .0014
.4299 0.826 (0.698-0.976) .0248
.0007 1.00 (0.848-1.19) .9611
.0091 0.855 (0.667-1.10) .2137
.0001 1.62 (1.32-2.00) .0001
.3990 1.05 (0.828-1.33) .6941
.0562 0.795 (0.565-1.12) .1863
.0110 0.966 (0.657-1.42) .8611
.0001 2.45 (2.06-2.93) .0001
.0157 1.43 (1.18-1.73) .0002
.9658 0.922 (0.767-1.11) .3542
.3202 0.900 (0.766-1.06) .2027
.1454 .3388
1.10 (0.833-1.45)
0.957 (0.741-1.24)
.0001 N/A
y and stenting; CHF, congestive heart failure; CI, confidence interval;N/A,nd p
ortalilinical equipoise.
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